Anne Floquet
Publications by Year
Research Areas
Ovarian cancer diagnosis and treatment, Uterine Myomas and Treatments, PARP inhibition in cancer therapy, Endometrial and Cervical Cancer Treatments, BRCA gene mutations in cancer
Most-Cited Works
- → Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer(2018)2,759 cited
- → Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial(2017)1,842 cited
- → Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial(2017)1,678 cited
- → Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial(2016)1,190 cited
- → Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial(2022)447 cited
- → Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm: A unicentre randomized trial with a 124-month median follow-up(1999)440 cited
- → Predictors of Early Death Risk in Older Patients Treated With First-Line Chemotherapy for Cancer(2012)424 cited
- → Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma(2017)403 cited
- → Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial(2021)399 cited
- → Incorporation of Pazopanib in Maintenance Therapy of Ovarian Cancer(2014)328 cited